TiumBio Co Ltd
KOSDAQ:321550
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
TiumBio Co Ltd
Common Shares Outstanding
TiumBio Co Ltd
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
TiumBio Co Ltd
KOSDAQ:321550
|
Common Shares Outstanding
₩26.7m
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Common Shares Outstanding
₩218.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Common Shares Outstanding
₩20.2m
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Common Shares Outstanding
₩18m
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Common Shares Outstanding
₩53.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
4%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Common Shares Outstanding
₩55.1m
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
TiumBio Co Ltd
Glance View
TiumBio Co., Ltd. engages in the development and manufacture of therapeutic drugs. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2019-11-22. The firm researches and develops small molecule drugs including endometriosis treatments, uterine fibroids treatments, cancer immunotherapy drugs; and new biopharmaceuticals including hemophilia treatments, and others.
See Also
What is TiumBio Co Ltd's Common Shares Outstanding?
Common Shares Outstanding
26.7m
KRW
Based on the financial report for Dec 31, 2024, TiumBio Co Ltd's Common Shares Outstanding amounts to 26.7m KRW.
What is TiumBio Co Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
3%
Over the last year, the Common Shares Outstanding growth was 7%. The average annual Common Shares Outstanding growth rates for TiumBio Co Ltd have been 4% over the past three years , 3% over the past five years .
